INTRODUCTION
There has been a substantial reduction in HIV-associated morbidity and mortality as a result of the global scale-up of antiretroviral therapy (ART). This is particularly true in low and middle income countries, such as those in the sub-Saharan African region, which bear the largest burden of HIV. [1] [2] [3] [4] This reduction in mortality has substantially increased life expectancy, with estimates now approaching that of the general population. [5] [6] [7] [8] Now that HIV-positive individuals are living longer lives, there has been increased attention towards the emerging dual burden of HIV and non-communicable diseases (NCDs), such as hypertension.
Key questions
What is already known about this topic?
▸ With advancements in HIV treatment and care, morbidity and mortality associated with HIV have decreased in many limited resource settings. ▸ Since people are living longer lives and experiencing less complications as a result of HIV, patients are now presenting to primary care providers with non-communicable diseases, including hypertension. ▸ At the population level, there is mixed evidence from low and middle income countries on the prevalence of hypertension among HIV-positive patients and its correlates.
What are the new findings?
▸ We retrospectively performed a chart review on 1996 patients from 2009 to 2013 to identify hypertension and correlates among patients attending an ambulatory HIV clinic in Kampala, Uganda. ▸ The overall prevalence of hypertension was 418/ 1996 (20.9%). This rose from 16.9% in 2009 to 32.3% in 2013.
Recommendations for policy
▸ There is a need to better integrate NCD care within the HIV clinical settings.
Hypertension in HIV-positive patients has been reported to be as low as 8.7% and as high as 45.9% in low and middle income countries. 9 10 Compared with the general population, some studies have suggested that hypertension is more prevalent among HIV-positive patients, 9 11 whereas other studies have reported that patients with HIV have lower levels of hypertension, compared with the general population. 12 13 Although there has been a comparable response to therapy for patients with hypertension with or without HIV infection, 9 the dual burden of NCDs and HIV provides a challenge to weak healthcare systems in low and middle income countries.
14 Establishing the magnitude of hypertension among HIV-positive patients and documenting the quality of care for these conditions within the HIV care setting provides an opportunity for improved care. The aim of this study was to determine the prevalence of hypertension, trends and associated factors among adults attending an ambulatory HIV clinic from 2009 to 2013 in Kampala, Uganda. Patients were eligible for inclusion if they were at least 18 years of age and visited the clinic between 2009 and 2014. Patients were randomly selected based on their year of intake into the HIV clinic and each patient was given a unique identifier at enrolment, so that patients do not appear on more than one sampling frame for each year. From this sampling frame, 400 patient charts from each year were randomly selected using a random number generator. For each of the 400 patient files selected, study variables were extracted.
METHODS

Study design and population
Study variables
The primary outcome variable was prevalence of hypertension. In each year, patients were considered as hypertensive if their systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg at three consecutive measurements separated by at least 2 weeks and taken after 5-10 min of rest in a sitting position or if they were known to be hypertensive and on treatment. 15 Adequate control for hypertension was defined as systolic blood pressure <140 mm Hg and diastolic blood pressure <90 mm Hg at the second and successive visits. 15 Additionally, we extracted data on demographic, clinical and biological characteristics including: WHO HIV disease stage, whether the patient was on ART, body mass index (BMI) and Karnofsky score that measures the degree of patient's functional impairment on a scale of 0-100.
Statistical analysis
Descriptive statistics were used to characterise the data. Prevalence of hypertension was calculated as the proportion of the study sample with a positive diagnosis, overall, and in each study year. Bivariable logistic regression was used to estimate the strength of the association between each study variable and the primary outcome, hypertension. A multivariable logistic model, adjusted for age and sex, was also constructed. Results are presented as ORs and adjusted ORs along with associated 95% CIs. All statistical tests were two-sided with α set at 0.05. Analyses were performed using STATA V.12 (StataCorp, College Station, Texas, USA).
RESULTS
In total, 2000 (400 per year from 2009 to 2013) patients were randomly selected from a sampling frame of 13 550. In 2009, four patients did not have any information on the outcome, so the final analytic sample consisted of 1996 patients. Of these, 418 were considered hypertensive, an overall study prevalence of 20.9%. (The Joint United Nations Programme on HIV/AIDS (UNAIDS), Gap Report). This demonstrates a rising double burden of HIV and hypertension, consistent with reports that as the proportion of HIV-positive patients achieving viral suppression on combination ART grows larger and these patients age, they are experiencing a widening spectrum of non-AIDS-related diseases. 1 Our study found an overall prevalence of 24.1% and a rising prevalence by year from 16.9% in 2009 to 32.3% in 2013. This is most likely due to the rising age of the patients accessing HIV care as well as the number of patients being put on antiretroviral therapy (ART). There might also be other factors which may not have been uncovered by the current study due to its retrospective nature. Compared with the general population in Uganda, the prevalence of hypertension in HIV-positive adults is within a similar range (21.2% vs 27.2%). 16 Mateen et al 10 in Uganda similarly reported a 28% prevalence of hypertension and 49% in those above 50 years with similar risk factors. In another Ugandan study, Sander et al 9 reported a lower prevalence of hypertension 8.0%, although when they considered only one elevated blood pressure reading, the prevalence rose to 26.3%. In contrast to Sander et al, 9 where 83% of participants diagnosed with hypertension were on antihypertensive medications, in our study only 20.9% were on recommended treatment for hypertension. In both studies, the most commonly used drugs were β-blockers and calcium channel blockers. 9 Our results provide evidence that hypertension has become an important NCD in the HIV-positive population with prevalence rates similar to that of the general population. In addition, our study shows that management of HIV-positive patients with hypertension is still inadequate. This is partly explained by the current HIV care guidelines in Uganda, which do not routinely include an NCD programme for HIV-positive patients attending the ambulatory clinics. Furthermore, most of the effort from the government and international agencies is currently focusing on HIV, tuberculosis and malaria, with less attention to the rising burden of hypertension in the HIV ageing population. Justice 1 recommends that focus must shift from a narrow interest in CD4 counts, HIV RNA and AIDS defining illnesses to determining the optimal management of HIV infection as a complex chronic disease in which the causes of morbidity and mortality are multiple and overlapping. We need a new paradigm of care with which to maximise functional status, minimise frailty and prolong life expectancy. 1 The authors propose a composite index that summarises a patient's risk of morbidity and mortality.
In this era of an ageing sub-Saharan African population on ART, we expect more patients to present with hypertension and other chronic conditions. This has become a substantial burden on resource-limited countries to manage a dual epidemic of infectious and chronic diseases. Few NCD programmes have been incorporated into HIV care and this highlights the importance of implementing screening, early diagnosis, and prevention measures for hypertension and other chronic diseases.
Our study has several strengths. The study was conducted in an ambulatory clinic, which serves a large proportion of the patients with HIV in urban Uganda. However, MJAP, being a centre of excellence in HIV, may not truly reflect what is happening elsewhere in the country where the access to expert service care may be more limited. Although we cannot use these data from a specialised urban HIV clinic to generalise hypertension care in Uganda, the findings demonstrate a missed opportunity for comprehensive care even among patients who frequently interface with healthcare providers. The findings therefore highlight a need for healthcare providers to develop indicators which can be used to monitor for improved care beyond HIV, in HIV-infected individuals with comorbidity. Additionally, the interpretation of our results must take into account some limitations. Most importantly, this was a chart review study and no patients were contacted; therefore, there were only a limited number of variables to extract and consider in the analysis. In particular, data on lifestyle factors important to hypertension, such as smoking status and alcohol intake, were sparse and not usable. Therefore, only a limited number of variables were available to construct a bivariable and multivariable model.
In conclusion, our study corroborates other studies that suggest an increasing prevalence of hypertension among HIV-positive patients in Uganda. Identifying risk factors will be important for clinicians to adequately manage a growing dual epidemic of infectious and chronic diseases in sub-Saharan Africa. 
